Tesmilifene, formerly known as YMB1002 and Depmpe, is a novel, small molecule that selectively targets multiple-drug resistant (MDR) tumor cells, sensitizing them to chemotherapy. Tesmilifene may offer clinical benefit in a number of tumor types and is being tested with a variety of chemotherapeutic regimens References: Deng T, Liu JC, Pritchard KI, Eisen A, Zacksenhaus E. Preferential killing of breast tumor initiating cells by N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine/tesmilifene. Clin Cancer Res. 2009 Jan 1;15(1):119-30. PubMed PMID: 19118039.
纯度:≥98%
CAS:92981-78-7